XBB.1.5 is a sub-lineage of the SARS-CoV-2 lineage XBB, and is currently estimated to have a large growth advantage over previously circulating lineages in North America (109%) and Europe (113%).
The number of COVID-19 cases has reached a record high in mainland China, peaking on 2 December 2022. In the past three weeks, incidence has fallen, likely also due to a lower number of tests being carried out, resulting in fewer infections being detected.
Since the end of October 2022 and as of week 47, several EU/EEA countries have indicated an increase in paediatric hospitalisations due to RSV infections causing bronchiolitis, amidst concurrent circulation of other respiratory pathogens, such as the influenza and SARS-CoV-2 viruses.
The 2022-2023 influenza (flu) season epidemic is off to an early start in the European region as concerns over Respiratory syncytial virus (RSV) rise and COVID-19 is still being a threat.